{
    "relation": [
        [
            "",
            "FPV 700 mg BID/RTV 100 mg BID",
            "FPV 700 mg BID/RTV 100 mg QD",
            "FPV, Other",
            "LPV, Standard Dose"
        ],
        [
            "Description",
            "Fosamprenavir 700 milligrams (mg) twice a day (BID)/Ritonavir 100 mg BID",
            "Fosamprenavir 700 mg BID/Ritonavir 100 mg once a day (QD)",
            "All other dosages of Fosamprenavir",
            "Lopinavir, Standard Dose"
        ]
    ],
    "pageTitle": "Fosamprenavir in Pts With Hepatic Impairment - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT01054586?sect=Xk015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988048.90/warc/CC-MAIN-20150728002308-00099-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 873571675,
    "recordOffset": 873554181,
    "tableOrientation": "VERTICAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details As this was an observational, retrospective study, no participants were recruited for participation in this study. For more information about this study, see the protocol in ClinicalTrials.gov and/or search for this study (111949) on http://www.gsk-clinicalstudyregister.com/. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Intervention A Standard dose Drug: Intervention B Reduced Dose Drug: Intervention C Drug: Intervention D Drug: Intervention E Interventions: Infection, Human Immunodeficiency Virus Condition: Observational\u00a0Model:\u00a0Cohort; \u00a0 Time\u00a0Perspective:\u00a0Prospective Study",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 FPV 700 mg BID/RTV 100 mg BID \u00a0 \u00a0 FPV 700 mg BID/RTV 100 mg QD \u00a0 \u00a0 FPV, Other \u00a0 \u00a0 LPV, Standard Dose \u00a0 STARTED \u00a0 \u00a0 43 \u00a0 \u00a0 15 \u00a0 \u00a0 8 \u00a0 \u00a0 101 \u00a0 COMPLETED \u00a0 \u00a0 43 \u00a0 \u00a0 15 \u00a0 \u00a0 8 \u00a0 \u00a0 101 \u00a0 NOT COMPLETED \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 Baseline Characteristics",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}